Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Saved in:
Bibliographic Details
Published in:International Journal of Antimicrobial Agents 2020-04, Vol.55 (4), p.105933-105933, Article 105933
Main Authors: Ko, Wen-Chien, Rolain, Jean-Marc, Lee, Nan-Yao, Chen, Po-Lin, Huang, Ching-Tai, Lee, Ping-Ing, Hsueh, Po-Ren
Format: Article
Language:English
Subjects:
Adenosine Monophosphate - analogs & derivatives
Adenosine Monophosphate - therapeutic use
Alanine - analogs & derivatives
Alanine - therapeutic use
Animals
Antiviral Agents - therapeutic use
Bacteriology
Betacoronavirus
Betacoronavirus - drug effects
Betacoronavirus - enzymology
Cardiology and cardiovascular system
Clinical Trials as Topic
Coronavirus disease 2019
Coronavirus Infections - drug therapy
COVID-19
DNA-Directed RNA Polymerases - antagonists & inhibitors
Emerging diseases
Human health and pathology
Humans
Infectious diseases
Life Sciences
Microbiology and Parasitology
Pandemics
Parasitology
Pneumonia, Viral - drug therapy
Remdesivir
SARS-CoV-2
Virology
Wuhan pneumonia
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2020.105933